DRI Capital announced the final closing of its U.S. $1.45 billion Drug Royalty III private equity financing fund.
With available debt, the equity financing Fund gives DRI U.S. $3 billion of purchasing power.
DRI will use the equity financing Fund to continue to execute on its strategy of acquiring royalties from global pharmaceutical and biotechnology companies, research institutions, universities, and inventors located worldwide.
Founded in 1992 as Drug Royalty Corporation, DRI Capital is the oldest and the largest healthcare royalty private equity financing manager in the world.
DRI, through its Drug Royalty managed funds, has acquired more than forty international life sciences royalty streams on such leading products as Cubicin, Enbrel, Myozyme, Remicade, Sensipar, Soliris, Stelara, Simponi, Synagis, Tysabri and Xolair, among many others over its 21 year history.
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity